Cellnovo Group (“Cellnovo” CLNV:EN Paris), a medical technology company marketing the first mobile, connected, all-in-one diabetes management system, announces the appointment of Thierry Moulin as the Company’s Chief Financial Officer with immediate effect.
Thierry Moulin joins Cellnovo from the multinational biopharmaceutical company Cellectis, where he served as Chief Financial Officer since 2014, overseeing a $228 million fundraise via a public listing on the Nasdaq in March 2015. During his time at Cellectis he also contributed to an extensive programme of restructuring through mergers, divestitures and reallocation of resources.